Drug intelligence / Profile preview

plasmacord

Development stage: Unknown
Administration: Subretinal, Intravitreal

Overview

PlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. It is being investigated for various therapeutic applications, including in clinical trials for conditions such as stress injuries, retinitis pigmentosa, and age-related macular degeneration.

Brand names: PlasmaCord

Beyond the preview

Go deeper on plasmacord.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plasmacord.

Explore the full profile